Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities

被引：10
|
作者：
Xie, Qingqing [1 ]
Zhang, Pengfei [1 ]
Wang, Yuanyuan [2 ]
Mei, Wuxuan [2 ]
Zeng, Changchun [1 ]
机构：
[1] Guangdong Med Univ, Shenzhen Longhua Dist Cent Hosp, Dept Med Lab, Shenzhen, Peoples R China
[2] Hubei Univ Sci & Technol, Xianning Med Coll, Xianning, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金：
中国国家自然科学基金;
关键词：
hepatocellular carcinoma; resistance; immune checkpoint inhibitors; mechanism; combination therapy; REGULATORY T-CELLS; LIVER-CANCER; PD-L1; EXPRESSION; BETA-CATENIN; OPEN-LABEL; IFN-GAMMA; PLUS; HETEROGENEITY; ATEZOLIZUMAB; BEVACIZUMAB;
D O I：
10.3389/fonc.2022.958720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of hepatocellular carcinoma over the past few years. However, only a limited proportion of patients with hepatocellular carcinoma respond to immunotherapy. Despite the significant breakthroughs, the molecular mechanisms that drive immune responses and evasion are largely unresolved. Predicting tumor response and resistance to immune checkpoint inhibitors is a significant challenge. In this review, we focus on the current research progress of immune checkpoint inhibitors in hepatocellular carcinoma. Importantly, this review highlights the underlying mechanisms of resistance to immune checkpoint inhibitors and summarizes potential strategies to overcome the resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
引用
收藏
页数：13
相关论文
共 50 条
  • [1] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
    Liu, Xiufeng
    Qin, Shukui
    [J]. ONCOLOGIST, 2019, 24 : S3 - S10
  • [2] Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
    Flynn, Michael J.
    Sayed, Anwar A.
    Sharma, Rohini
    Siddique, Abdul
    Pinato, David J.
    [J]. HEPATOLOGY, 2019, 69 (05) : 2258 - 2270
  • [3] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
    Liu, Hao-Tian
    Jiang, Meng-Jie
    Deng, Zhu-Jian
    Li, Le
    Huang, Jian-Li
    Liu, Zhen-Xiu
    Li, Le-Qun
    Zhong, Jian-Hong
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
    Cheng, Ann-Lii
    Hsu, Chiun
    Chan, Stephen L.
    Choo, Su-Pin
    Kudo, Masatoshi
    [J]. JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 307 - 319
  • [5] Primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma
    Cui, Xiaowen
    Ruan, Minghao
    Li, Yao
    Yang, Cheng
    Zhou, Liuyu
    Zhang, Jin
    Jin, Riming
    Wu, Dong
    Wang, Ruoyu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology
    Moskalenko, Y.
    [J]. REGULATORY MECHANISMS IN BIOSYSTEMS, 2024, 15 (01) : 83 - 91
  • [7] Immune checkpoint inhibitors for hepatocellular carcinoma
    El Dika, Imane
    Khalil, Danny N.
    Abou-Alfa, Ghassan K.
    [J]. CANCER, 2019, 125 (19) : 3312 - 3319
  • [8] Immune checkpoint inhibitors for hepatocellular carcinoma
    Jensen, Christopher E.
    Loaiza-Bonilla, Arturo
    Bonilla-Reyes, Paula A.
    [J]. HEPATIC ONCOLOGY, 2016, 3 (03) : 201 - 211
  • [9] Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
    Pinter, Matthias
    Scheiner, Bernhard
    Pinato, David J.
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (08): : 760 - 770
  • [10] Immune checkpoint inhibitors in lymphoma: challenges and opportunities
    Hatic, Haris
    Sampat, Devi
    Goyal, Gaurav
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (12)
12345